ValGenesis has announced that one of the world's largest, top rated life science companies has chosen to implement its 100% paperless Validation Lifecycle Management System (VLMS) across all its global sites to manage the corporate validation lifecycle process.
Mayne Pharma Group, a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, has launched LEXETTE (halobetasol propionate) Foam 0.05% in the US.
Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), has announced the acquisition of Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma.
apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy, announced that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma.
NextPharma, a European pharmaceutical contract development and manufacturing organization (CDMO), has agreed to acquire Santen’s Tampere manufacturing facility and associated operations.
Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of US rights of Synagis (palivizumab) from AstraZeneca in a deal valued at around $1.6bn.
Circassia Pharmaceuticals has agreed to acquire the exclusive commercialization rights of AIT Therapeutics’ ventilator compatible nitric oxide product AirNOvent in the US and China.
BioNTech, a biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB Discovery, a unique player in the generation and development of sophisticated and therapeutically relevant monoclonal antibodies (mAbs), have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.
Aurobindo Pharma’s subsidiary Acrotech Biopharma has agreed to acquire seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in a deal valued at around $300m.
Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland China.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.